Experimental t cell therapy targets 'Undruggable' cancer mutation
NCT ID NCT06546150
Summary
This early-stage trial is testing a new T cell therapy called RE002 for people with advanced solid tumors that have a specific KRAS G12D mutation. The study will enroll 30 patients to determine safe dosage levels and see if the treatment can shrink tumors. Participants will receive a single infusion of their own genetically modified immune cells after undergoing chemotherapy to prepare their body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12D are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450008, China
Contact
Conditions
Explore the condition pages connected to this study.